Literature DB >> 15796397

Use of an embolic protection system during endovascular recanalization of a totally occluded cervical internal carotid artery at the chronic stage. Case report.

Tomoaki Terada1, Hiroo Yamaga, Tomoyuki Tsumoto, Osamu Masuo, Toru Itakura.   

Abstract

A symptomatic internal carotid artery (ICA) occlusion with hemodynamic compromise was treated at its chronic stage by using an endovascular technique. An embolic protection system was used during the recanalization procedure to prevent stroke by reversing the flow from the distal ICA to the common carotid artery. The totally occluded ICA was completely recanalized through percutaneous transluminal angioplasty and stent placement. The patient's symptom (transient ischemic attack) disappeared completely after treatment with no new neurological deficit. Single-photon emission computerized tomography findings confirmed improvement of the hemodynamic compromise, and no new high-intensity spots appeared on diffusion-weighted magnetic resonance imaging after treatment. This case shows that endovascular recanalization by using an embolic protection device can be considered as an alternative treatment for symptomatic ICA occlusion with hemodynamic compromise and refractoriness to antiplatelet therapy, even in the chronic stage of the illness.

Entities:  

Mesh:

Year:  2005        PMID: 15796397     DOI: 10.3171/jns.2005.102.3.0558

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  12 in total

1.  Stenting and angioplasty of the symptomatic chronically occluded carotid artery.

Authors:  A J Thomas; R Gupta; A H Tayal; A B Kassam; M B Horowitz; T G Jovin
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

2.  Precision Stroke Animal Models: the Permanent MCAO Model Should Be the Primary Model, Not Transient MCAO.

Authors:  Devin W McBride; John H Zhang
Journal:  Transl Stroke Res       Date:  2017-07-17       Impact factor: 6.829

3.  Management of Bilateral Carotid Occlusive Disease.

Authors:  Ashutosh P Jadhav; Andrew F Ducruet; Brian T Jankowitz; Tudor G Jovin
Journal:  Interv Neurol       Date:  2016-01-06

4.  Successful carotid stenting for chronic total occlusion of the internal carotid artery.

Authors:  Won Ho Kim; Pil-Ki Min; Dong Jun Kim; Won-Heum Shim
Journal:  Korean Circ J       Date:  2010-06-29       Impact factor: 3.243

5.  Percutaneous transluminal angioplasty and stenting for chronic total occlusion of intracranial carotid artery: a case report.

Authors:  H Ishihara; N Sakai; T Kuroiwa; M Sakaguchi; A Morizane; C Sakai; T Yano; R Kajikawa; H Yamagami; J Kobayashi
Journal:  Interv Neuroradiol       Date:  2006-12-13       Impact factor: 1.610

6.  Delayed Recanalization Promotes Functional Recovery in Rats Following Permanent Middle Cerebral Artery Occlusion.

Authors:  Devin William McBride; Guangyong Wu; Derek Nowrangi; Jerry J Flores; Liang Hui; Paul R Krafft; John H Zhang
Journal:  Transl Stroke Res       Date:  2018-01-21       Impact factor: 6.829

7.  Carotid angioplasty with stenting for chronic internal carotid artery occlusion: technical note.

Authors:  Nozomu Kobayashi; Shigeru Miyachi; Kenichi Hattori; Toshihiko Tanasawa; Takeshi Okada; Otone Endo; Naohito Yamamoto
Journal:  Neuroradiology       Date:  2006-08-10       Impact factor: 2.804

8.  Protected endovascular revascularization of subacute and chronic total occlusion of the internal carotid artery.

Authors:  M Shojima; S Nemoto; A Morita; T Miyata; K Namba; Y Tanaka; E Watanabe
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-22       Impact factor: 3.825

9.  Wire-probing technique to revascularize subacute or chronic internal carotid artery occlusion.

Authors:  K Namba; M Shojima; S Nemoto
Journal:  Interv Neuroradiol       Date:  2012-09-10       Impact factor: 1.610

Review 10.  Delayed Recanalization-How Late Is Not Too Late?

Authors:  Ruiqing Kang; Marcin Gamdzyk; Hong Tang; Yujie Luo; Cameron Lenahan; John H Zhang
Journal:  Transl Stroke Res       Date:  2020-11-20       Impact factor: 6.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.